bioRxiv Science⌕ Search

Biology subjects

Amaya, L.

Publications and source records attributed to Amaya, L..

3 recordsLinked to original sources

Intra-host IRES heterogeneity shapes hepatitis C virus translation through epistatic and population-level effects

Hepatitis C virus (HCV) circulates within each patient as a diverse population of closely related genomes, yet RNA functional properties are commonly inferred from a single consensus or dominant genome. The contribution of non-coding intra-host variability, particularly within the internal ribosome entry site (IRES), to translational efficiency remains poorly defined. Here we investigated how naturally occurring HCV IRES variation influences viral RNA translation. Complete IRES sequences from chronically infected patients were analyzed using molecular cloning, bicistronic reporters, full-length replication-deficient viral RNAs and reconstructed intra-host populations. We found that natural IRES mutations displayed context-dependent effects, and combinations of mutations produced translational phenotypes that could not be predicted from the corresponding single mutations, consistent with intragenic epistasis. Moreover, several variants behaved differently in bicistronic reporters and full-length viral RNAs, demonstrating that both genomic and cellular context shape IRES function. Reconstructed genotype 1a populations largely reproduced the activity of their dominant haplotypes. In contrast, reconstructed genotype 3a populations translated substantially more efficiently than their corresponding dominant sequences, showing that low-frequency variants can collectively modulate translation at the population level. These findings demonstrate that the translational phenotype of HCV cannot always be inferred from the dominant sequence alone and identify epistasis, genomic context, and intra-host population composition as interacting determinants of viral RNA translation. ImportanceHepatitis C virus (HCV) exists within each infected person as a diverse population of closely related viruses rather than as a single genetic sequence. This study shows that natural variation in a key RNA region controlling viral protein production can alter how efficiently the virus functions, and that these effects depend on combinations of mutations rather than on individual changes alone. By analyzing complete viral RNAs in addition to widely used reporter systems, we demonstrate that the full viral genome can substantially influence the activity of this regulatory region, providing a more realistic view of how translation occurs during natural infection. Our findings also reveal that rare viral variants can collectively shape the behavior of the viral population, challenging the common practice of relying on a single dominant sequence to represent an infection. These results provide new insight into how genetic diversity drives HCV evolution and adaptation.

molecular biology↗

Development of iPSC-Derived T Cells Targeting EGFR Neoantigens in Non-Small Cell Lung Cancer

A long-sought goal of cancer immunotherapy is to mass-produce T cells that specifically target tumor neoantigens. One decisive challenge is the identification of neoantigens derived from cancer driver genes. Here, we identify T cells that recognize the NSCLC-associated EGFR C797S mutation, which confers resistance to current inhibitors and is linked to poor prognosis. To overcome limitations in T cell availability, we reprogrammed EGFR C797S-specific T cells into induced pluripotent stem cells (iPSCs) and re-differentiated them into CD8 T cells. These iPSC-derived T cells specifically recognized the EGFR C797S mutation and effectively killed cancer cells expressing this mutation. Our findings underscore the potential of targeting driver mutation-derived neoantigens for immunotherapy and demonstrate that iPSC-derived T cells can mediate antitumor effects. Collectively, this approach combining neoantigen identification with T cell reprogramming may offer a promising strategy for targeting drug-resistant tumors.

immunology↗

Epigenetic signature and key transcriptional regulators of human antigen-specific type 1 regulatory T cells

Human adaptive immunity is orchestrated by effector and regulatory T (Treg) cells. Natural Tregs arise in the thymus where they are shaped to recognize self-antigens, while type 1 Tregs or Tr1 cells are induced from conventional peripheral CD4+ T cells in response to peripheral antigens, such as alloantigens and allergens. Tr1 cells have been developed as a potential therapy for inducing antigen-specific tolerance, because they can be rapidly differentiated in vitro in response to a target antigen. However, the epigenetic landscape and the identity of transcription factors (TFs) that regulate differentiation, phenotype, and functions of human antigen-specific Tr1 cells is largely unknown, hindering Tr1 research and broader clinical development. Here, we reveal the unique epigenetic signature of antigen-specific Tr1 cells, and TFs that regulate their differentiation, phenotype and function. We showed that in vitro induced antigen-specific Tr1 cells are distinct both clonally and transcriptionally from natural Tregs and other conventional CD4+ T cells on a single-cell level. An integrative analysis of Tr1 cell epigenome and transcriptome identified a TF signature unique to antigen-specific Tr1 cells, and predicted that IRF4, BATF, and MAF act as their transcriptional regulators. Using functional genomics, we showed that each of these TFs play a non-redundant role in regulating Tr1 cell differentiation, suppressive function, and expression of co-inhibitory and cytotoxic proteins. By using the Tr1-specific TF signature as a molecular fingerprint, we tracked Tr1 cells in peripheral blood of recipients of allogeneic hematopoietic stem cell transplantation treated with adoptive Tr1 cell therapy. Furthermore, the same signature identified Tr1 cells in resident CD4+ T cells in solid tumors. Altogether, these results reveal the epigenetic signature and the key transcriptional regulators of human Tr1 cells. These data will guide mechanistic studies of human Tr1 cell biology and the development and optimization of adoptive Tr1 cell therapies.

immunology↗